[HTML][HTML] The recent advancement of TCR-T cell therapies for cancer treatment: TCR-T cell therapies for cancer treatment
X Zhao, S Shao, L Hu - Acta Biochimica et Biophysica Sinica, 2024 - pmc.ncbi.nlm.nih.gov
Adoptive cell therapies involve infusing engineered immune cells into cancer patients to
recognize and eliminate tumor cells. Adoptive cell therapy, as a form of living drug, has …
recognize and eliminate tumor cells. Adoptive cell therapy, as a form of living drug, has …
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
HM Murdock, VT Ho, JS Garcia - Frontiers in Immunology, 2024 - frontiersin.org
Acute Myeloid Leukemia (AML) is the prototype of cancer genomics as it was the first
published cancer genome. Large-scale next generation/massively parallel sequencing …
published cancer genome. Large-scale next generation/massively parallel sequencing …
Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia
P Zhang, T Wang, G Cui, R Ye, W Wan, T Liu… - Advanced …, 2024 - Wiley Online Library
Hematological malignancies (HM) like acute myeloid leukemia (AML) are often intractable.
Cancer vaccines possibly inducing robust and broad anti‐tumor immune responses may be …
Cancer vaccines possibly inducing robust and broad anti‐tumor immune responses may be …
Broadening the horizon: potential applications of CAR-T cells beyond current indications
H Karsten, L Matrisch, S Cichutek, W Fiedler… - Frontiers in …, 2023 - frontiersin.org
Engineering immune cells to treat hematological malignancies has been a major focus of
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …
research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several …
Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1/2) Mutations in Acute Myeloid Leukemia and Their Relevance as …
NE Struckman, RCM de Jong, MW Honders, SAI Smith… - Biomedicines, 2024 - mdpi.com
DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 and 2 (IDH1/2) are
genes involved in epigenetic regulation, each mutated in 7–23% of patients with acute …
genes involved in epigenetic regulation, each mutated in 7–23% of patients with acute …
T cells take aim in AML: targeting IDH2
M Subklewe - Blood, 2024 - ashpublications.org
In this issue of Blood, Leung et al 1 present preclinical findings demonstrating the potential
of neoantigen-specific T cells to recognize acute myeloid leukemia (AML) driver mutations …
of neoantigen-specific T cells to recognize acute myeloid leukemia (AML) driver mutations …
Tunable Universal OR-gated CAR T cells for AML
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized by antigen
heterogeneity and poor prognosis. A potential therapeutic approach to address this …
heterogeneity and poor prognosis. A potential therapeutic approach to address this …